Metis Precision Medicine Raises €450k in Seed Funding

Metis Precision Medicine, a Turin, Italy-based developer of oncologic therapies, raised €450k in seed funding.

Club degli Investitori, a regional business angel network operating in Piedmont, made the investment.

Founded in 2017 as a “Benefit Company” by Prof Paolo Comoglio, Metis Precision Medicine develops a medicine that inducts the clinical remission and prolong patient’s life in selected cases.
The company, which has an IP portfolio related to monoclonal antibodies vs an oncogene (Met), intends to use the funds to conduct the pre-clinical stage to finalize the deposit of a new IP.



Join the discussion